{
    "2018-05-31": [
        [
            {
                "time": "2018-05-29",
                "original_text": "A Look at GlaxoSmithKline’s Valuation on May 29",
                "features": {
                    "keywords": [
                        "GlaxoSmithKline",
                        "valuation"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-05-30",
                "original_text": "How Novartis’s Business Segments Did in Q1",
                "features": {
                    "keywords": [
                        "Novartis",
                        "Q1",
                        "business segments"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-05-31",
                "original_text": "Analyzing Novartis’s Revenue in Q1",
                "features": {
                    "keywords": [
                        "Novartis",
                        "revenue",
                        "Q1"
                    ],
                    "sentiment_score": 0.65,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-06-01",
                "original_text": "FDA Moves to Make Life Easier for Generic Drug Companies",
                "features": {
                    "keywords": [
                        "FDA",
                        "generic drugs",
                        "regulation"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-06-02",
                "original_text": "ASCO Conference Preview: Here's What Biotech Investors Need to Watch",
                "features": {
                    "keywords": [
                        "ASCO",
                        "biotech",
                        "investors"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-06-03",
                "original_text": "The Swiss Stock Market Finished Lower After Late Sell-Off",
                "features": {
                    "keywords": [
                        "Swiss stock market",
                        "sell-off"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "general market"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            },
            {
                "time": "2018-06-04",
                "original_text": "George Soros Bought This Clinical-Stage Biotech Stock. Should You?",
                "features": {
                    "keywords": [
                        "George Soros",
                        "biotech",
                        "investment"
                    ],
                    "sentiment_score": 0.7,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "biotechnology"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-06-05",
                "original_text": "Outcome Health names 4 new board members",
                "features": {
                    "keywords": [
                        "Outcome Health",
                        "board members"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "healthcare"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            },
            {
                "time": "2018-06-06",
                "original_text": "Assessing GlaxoSmithKline’s Quarterly Revenues",
                "features": {
                    "keywords": [
                        "GlaxoSmithKline",
                        "quarterly revenues"
                    ],
                    "sentiment_score": 0.65,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-06-07",
                "original_text": "How Novartis’s Valuation Compares",
                "features": {
                    "keywords": [
                        "Novartis",
                        "valuation"
                    ],
                    "sentiment_score": 0.6,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "false",
                    "causal_impact": "neutral",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2018-06-08",
                "original_text": "FDA Moves to Ease Way for Generic Drugmakers",
                "features": {
                    "keywords": [
                        "FDA",
                        "generic drugmakers",
                        "regulation"
                    ],
                    "sentiment_score": 0.8,
                    "policy_related": "true",
                    "investment_strategy": "false",
                    "sector_focus": [
                        "pharmaceuticals"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": "neutral"
                }
            }
        ]
    ]
}